670 related articles for article (PubMed ID: 8120917)
1. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
[TBL] [Abstract][Full Text] [Related]
2. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
Spicer DV; Pike MC; Pike A; Rude R; Shoupe D; Richardson J
Contraception; 1993 May; 47(5):427-44. PubMed ID: 8390340
[TBL] [Abstract][Full Text] [Related]
3. The prevention of breast cancer through reduced ovarian steroid exposure.
Spicer DV; Pike MC
Acta Oncol; 1992; 31(2):167-74. PubMed ID: 1622631
[TBL] [Abstract][Full Text] [Related]
4. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
Gram IT; Ursin G; Spicer DV; Pike MC
Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1117-20. PubMed ID: 11700258
[TBL] [Abstract][Full Text] [Related]
5. Contraception and cancer prevention.
Ursin G; Spicer DV; Pike MC
Adv Contracept Deliv Syst; 1994; 10(3-4):369-86. PubMed ID: 12287845
[TBL] [Abstract][Full Text] [Related]
6. Sex steroids and breast cancer prevention.
Spicer DV; Pike MC
J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
[TBL] [Abstract][Full Text] [Related]
7. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
Ruchhoft EA; Elkind-Hirsch KE; Malinak R
Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
[TBL] [Abstract][Full Text] [Related]
8. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
9. The detection of changes in mammographic densities.
Ursin G; Astrahan MA; Salane M; Parisky YR; Pearce JG; Daniels JR; Pike MC; Spicer DV
Cancer Epidemiol Biomarkers Prev; 1998 Jan; 7(1):43-7. PubMed ID: 9456242
[TBL] [Abstract][Full Text] [Related]
10. [Hormonal contraception].
Van Cauwenberge JR
Rev Med Liege; 1992 May; 47(5):221-36. PubMed ID: 1604074
[TBL] [Abstract][Full Text] [Related]
11. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
[TBL] [Abstract][Full Text] [Related]
12. Hormonal inhibition of the endometrium for resectoscopic endometrial ablation.
Brooks PG; Serden SP; Davos I
Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1601-6; discussion 1606-8. PubMed ID: 1904683
[TBL] [Abstract][Full Text] [Related]
13. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
14. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management.
Vorherr H
Am J Obstet Gynecol; 1986 Jan; 154(1):161-79. PubMed ID: 3511705
[TBL] [Abstract][Full Text] [Related]
15. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
Parkington HC; Lipton A
J Endocrinol; 1976 Aug; 70(2):223-7. PubMed ID: 965882
[TBL] [Abstract][Full Text] [Related]
16. Exogenous estrogen and endometrial carcinoma: case-control and incidence study.
McDonald TW; Annegers JF; O'Fallon WM; Dockerty MB; Malkasian GD; Kurland LT
Am J Obstet Gynecol; 1977 Mar; 127(6):572-80. PubMed ID: 190887
[TBL] [Abstract][Full Text] [Related]
17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
[TBL] [Abstract][Full Text] [Related]
18. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
[TBL] [Abstract][Full Text] [Related]
19. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
20. Depo Provera. Position paper on clinical use, effectiveness and side effects.
Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
